Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Go read previous pr's
They are taking a line of credit to repurchase stock and expand the biz
They just had a shareholders meeting and the CEO brought in the auditor and valuation people from dos.
I'm on an iPhone so it's hard to write. So just go check out the past few pr's
Guaranteed you will like what u see
Guys just look at the recent news! This stock is ridiculously undervalued!
I'm in! Let's go!
again, the lady on the front is being very rude. she wont transfer me or send me to his vmail.
Will do
The lady didn't transfer me
On the phone with HGA trying to confirm. 318-255-6825
INSYS Announces NDA PDUFA Date for Fentanyl SL Spray!!!
INSYS Announces NDA PDUFA Date for Fentanyl SL Spray
Insys Therapeutics (PL) (USOTC:NEOL)
Intraday Stock Chart
Today : Friday 20 May 2011
Click Here for more Insys Therapeutics (PL) Charts.
INSYS Therapeutics, Inc. (formerly NeoPharm, Inc.) (Other OTC:NEOL) today announced that the U.S. Food and Drug Administration (FDA) has provided an anticipated Prescription Drug User Fee Act (PDUFA) goal date of January 4, 2012 for its review of the New Drug Application (NDA) for Fentanyl SL Spray.
“We look forward to working with the FDA during the review process and, if approved, making this proprietary product available for patients who suffer from breakthrough cancer pain,” said Larry Dillaha, M.D., INSYS Chief Medical Officer.
About Insys Therapeutics, Inc.
Insys Therapeutics, Inc., based in Phoenix, Arizona, is developing and seeking to commercialize innovative pharmaceutical products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care. Insys utilizes proprietary technologies to develop product candidates that address the clinical shortcomings of existing commercial products. Additional information can be obtained by visiting the Insys Therapeutics web site at www.insysrx.com.
Forward Looking Statements
This press release contains "forward-looking statements" that may be identified by use of such words as "expects," "intends," "hopes," "anticipates," "believes," "could," "may," “look forward to” and "estimates," and other similar expressions, but these words are not the exclusive means of identifying such statements. Such statements include, but are not limited to, statements relating to the FDA's review of the Fentanyl SL Spray NDA, the status of Insys’ drug development programs, the prospects, potential regulatory approval and potential commercialization of Fentanyl SL Spray, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to Insys’ ability to obtain financing to fund its operations, difficulties or delays in the development, receipt of regulatory approval, production, and marketing of Insys’ product candidates, Insys’ ability to hire, train and successfully deploy a sales force, unexpected adverse side effects or inadequate therapeutic efficacy of Insys’ product candidates, and the uncertainty of patent protection for Insys’ intellectual property or trade secrets. Such statements are based on management's current expectations, but actual results may differ materially due to various factors, including those risks and uncertainties mentioned in this press release. For the foregoing reasons, you should not rely on these forward-looking statements as a prediction of actual future results.
INSYS Announces NDA PDUFA Date for Fentanyl SL Spray!!!
INSYS Announces NDA PDUFA Date for Fentanyl SL Spray
Insys Therapeutics (PL) (USOTC:NEOL)
Intraday Stock Chart
Today : Friday 20 May 2011
Click Here for more Insys Therapeutics (PL) Charts.
INSYS Therapeutics, Inc. (formerly NeoPharm, Inc.) (Other OTC:NEOL) today announced that the U.S. Food and Drug Administration (FDA) has provided an anticipated Prescription Drug User Fee Act (PDUFA) goal date of January 4, 2012 for its review of the New Drug Application (NDA) for Fentanyl SL Spray.
“We look forward to working with the FDA during the review process and, if approved, making this proprietary product available for patients who suffer from breakthrough cancer pain,” said Larry Dillaha, M.D., INSYS Chief Medical Officer.
About Insys Therapeutics, Inc.
Insys Therapeutics, Inc., based in Phoenix, Arizona, is developing and seeking to commercialize innovative pharmaceutical products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care. Insys utilizes proprietary technologies to develop product candidates that address the clinical shortcomings of existing commercial products. Additional information can be obtained by visiting the Insys Therapeutics web site at www.insysrx.com.
Forward Looking Statements
This press release contains "forward-looking statements" that may be identified by use of such words as "expects," "intends," "hopes," "anticipates," "believes," "could," "may," “look forward to” and "estimates," and other similar expressions, but these words are not the exclusive means of identifying such statements. Such statements include, but are not limited to, statements relating to the FDA's review of the Fentanyl SL Spray NDA, the status of Insys’ drug development programs, the prospects, potential regulatory approval and potential commercialization of Fentanyl SL Spray, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to Insys’ ability to obtain financing to fund its operations, difficulties or delays in the development, receipt of regulatory approval, production, and marketing of Insys’ product candidates, Insys’ ability to hire, train and successfully deploy a sales force, unexpected adverse side effects or inadequate therapeutic efficacy of Insys’ product candidates, and the uncertainty of patent protection for Insys’ intellectual property or trade secrets. Such statements are based on management's current expectations, but actual results may differ materially due to various factors, including those risks and uncertainties mentioned in this press release. For the foregoing reasons, you should not rely on these forward-looking statements as a prediction of actual future results.
i thought this company is in the biowaste field. what are they doing going into the music field. did the biowaste direction of the company fail/
NEOL - INSYS Announces NDA PDUFA Date for Fentanyl SL Spray
INSYS Announces NDA PDUFA Date for Fentanyl SL Spray
Insys Therapeutics (PL) (USOTC:NEOL)
Intraday Stock Chart
Today : Friday 20 May 2011
Click Here for more Insys Therapeutics (PL) Charts.
INSYS Therapeutics, Inc. (formerly NeoPharm, Inc.) (Other OTC:NEOL) today announced that the U.S. Food and Drug Administration (FDA) has provided an anticipated Prescription Drug User Fee Act (PDUFA) goal date of January 4, 2012 for its review of the New Drug Application (NDA) for Fentanyl SL Spray.
“We look forward to working with the FDA during the review process and, if approved, making this proprietary product available for patients who suffer from breakthrough cancer pain,” said Larry Dillaha, M.D., INSYS Chief Medical Officer.
About Insys Therapeutics, Inc.
Insys Therapeutics, Inc., based in Phoenix, Arizona, is developing and seeking to commercialize innovative pharmaceutical products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care. Insys utilizes proprietary technologies to develop product candidates that address the clinical shortcomings of existing commercial products. Additional information can be obtained by visiting the Insys Therapeutics web site at www.insysrx.com.
Forward Looking Statements
This press release contains "forward-looking statements" that may be identified by use of such words as "expects," "intends," "hopes," "anticipates," "believes," "could," "may," “look forward to” and "estimates," and other similar expressions, but these words are not the exclusive means of identifying such statements. Such statements include, but are not limited to, statements relating to the FDA's review of the Fentanyl SL Spray NDA, the status of Insys’ drug development programs, the prospects, potential regulatory approval and potential commercialization of Fentanyl SL Spray, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to Insys’ ability to obtain financing to fund its operations, difficulties or delays in the development, receipt of regulatory approval, production, and marketing of Insys’ product candidates, Insys’ ability to hire, train and successfully deploy a sales force, unexpected adverse side effects or inadequate therapeutic efficacy of Insys’ product candidates, and the uncertainty of patent protection for Insys’ intellectual property or trade secrets. Such statements are based on management's current expectations, but actual results may differ materially due to various factors, including those risks and uncertainties mentioned in this press release. For the foregoing reasons, you should not rely on these forward-looking statements as a prediction of actual future results.
NEOL - INSYS Announces NDA PDUFA Date for Fentanyl SL Spray!!!
THIS WAS ANNOUNCED 20 MINUTES AGO, VOLUME IS STARTING TO POUR IN!!!
INSYS Announces NDA PDUFA Date for Fentanyl SL Spray!!!
INSYS Announces NDA PDUFA Date for Fentanyl SL Spray
Insys Therapeutics (PL) (USOTC:NEOL)
Intraday Stock Chart
Today : Friday 20 May 2011
Click Here for more Insys Therapeutics (PL) Charts.
INSYS Therapeutics, Inc. (formerly NeoPharm, Inc.) (Other OTC:NEOL) today announced that the U.S. Food and Drug Administration (FDA) has provided an anticipated Prescription Drug User Fee Act (PDUFA) goal date of January 4, 2012 for its review of the New Drug Application (NDA) for Fentanyl SL Spray.
“We look forward to working with the FDA during the review process and, if approved, making this proprietary product available for patients who suffer from breakthrough cancer pain,” said Larry Dillaha, M.D., INSYS Chief Medical Officer.
About Insys Therapeutics, Inc.
Insys Therapeutics, Inc., based in Phoenix, Arizona, is developing and seeking to commercialize innovative pharmaceutical products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care. Insys utilizes proprietary technologies to develop product candidates that address the clinical shortcomings of existing commercial products. Additional information can be obtained by visiting the Insys Therapeutics web site at www.insysrx.com.
Forward Looking Statements
This press release contains "forward-looking statements" that may be identified by use of such words as "expects," "intends," "hopes," "anticipates," "believes," "could," "may," “look forward to” and "estimates," and other similar expressions, but these words are not the exclusive means of identifying such statements. Such statements include, but are not limited to, statements relating to the FDA's review of the Fentanyl SL Spray NDA, the status of Insys’ drug development programs, the prospects, potential regulatory approval and potential commercialization of Fentanyl SL Spray, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to Insys’ ability to obtain financing to fund its operations, difficulties or delays in the development, receipt of regulatory approval, production, and marketing of Insys’ product candidates, Insys’ ability to hire, train and successfully deploy a sales force, unexpected adverse side effects or inadequate therapeutic efficacy of Insys’ product candidates, and the uncertainty of patent protection for Insys’ intellectual property or trade secrets. Such statements are based on management's current expectations, but actual results may differ materially due to various factors, including those risks and uncertainties mentioned in this press release. For the foregoing reasons, you should not rely on these forward-looking statements as a prediction of actual future results.
NEOL - FDA NEWS, CHECK IT OUT!!!
INSYS Announces NDA PDUFA Date for Fentanyl SL Spray
Insys Therapeutics (PL) (USOTC:NEOL)
Intraday Stock Chart
Today : Friday 20 May 2011
Click Here for more Insys Therapeutics (PL) Charts.
INSYS Therapeutics, Inc. (formerly NeoPharm, Inc.) (Other OTC:NEOL) today announced that the U.S. Food and Drug Administration (FDA) has provided an anticipated Prescription Drug User Fee Act (PDUFA) goal date of January 4, 2012 for its review of the New Drug Application (NDA) for Fentanyl SL Spray.
“We look forward to working with the FDA during the review process and, if approved, making this proprietary product available for patients who suffer from breakthrough cancer pain,” said Larry Dillaha, M.D., INSYS Chief Medical Officer.
About Insys Therapeutics, Inc.
Insys Therapeutics, Inc., based in Phoenix, Arizona, is developing and seeking to commercialize innovative pharmaceutical products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care. Insys utilizes proprietary technologies to develop product candidates that address the clinical shortcomings of existing commercial products. Additional information can be obtained by visiting the Insys Therapeutics web site at www.insysrx.com.
Forward Looking Statements
This press release contains "forward-looking statements" that may be identified by use of such words as "expects," "intends," "hopes," "anticipates," "believes," "could," "may," “look forward to” and "estimates," and other similar expressions, but these words are not the exclusive means of identifying such statements. Such statements include, but are not limited to, statements relating to the FDA's review of the Fentanyl SL Spray NDA, the status of Insys’ drug development programs, the prospects, potential regulatory approval and potential commercialization of Fentanyl SL Spray, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to Insys’ ability to obtain financing to fund its operations, difficulties or delays in the development, receipt of regulatory approval, production, and marketing of Insys’ product candidates, Insys’ ability to hire, train and successfully deploy a sales force, unexpected adverse side effects or inadequate therapeutic efficacy of Insys’ product candidates, and the uncertainty of patent protection for Insys’ intellectual property or trade secrets. Such statements are based on management's current expectations, but actual results may differ materially due to various factors, including those risks and uncertainties mentioned in this press release. For the foregoing reasons, you should not rely on these forward-looking statements as a prediction of actual future results.
130k volume!!!
HERE WE Go!!!!
its taking off!!!!
killer news!!!!!
bye bye
Already out. Just waiting for my divvy. Don't really trust them.
Hmmm seems like a good play
What's the company share structure
I dont know I guess we will see
you could've made some nice coin.
Guys I was in this stock before the name was changed, check my history. I have also posted tons I'd DD. Listen to me when I say this "STAY FAR AWAY, THE PRINCIPALS OF THIS COMPANY CANNOT BE TRUSTED".
~treo
Why didn't u ask about the divvy?
Did u see the close? This company still has record revenues. They are trading around what it should be, I believe.
This stock is bound to take off. There is major short action going on, there must be a correction. Get ready for a short squeeze!!!
-Treo
whose selling etmm at .0189?? remove yours and we pop to .033
Don't be fooled volume is picking up!
Let's knock out the 4'sss very thin!
its all awareness! if we can show people what we have here, it will take off!
hit .02!!
NEWS! 10Q is postponed again!
Think this may be a good one
do they have any companies yet?
ask is $1.01 im sorry guys but im putting in a sell for $1.00 .......
1 min left to get in!!
care to point this out, i see it holding steady>>>>>you also bought 150k right? go away.
yes it will! ask just moved to .15